Comparative Pharmacology
Head-to-head clinical analysis: SODIUM IODIDE I 131 versus VIZAMYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM IODIDE I 131 versus VIZAMYL.
SODIUM IODIDE I 131 vs VIZAMYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium iodide I 131 is a radioactive isotope that emits beta particles and gamma rays. It is taken up by the thyroid gland via the sodium-iodide symporter and incorporated into thyroid hormones. The beta radiation causes local destruction of thyroid tissue, reducing hormone production and treating hyperthyroidism or thyroid cancer.
Vizamyl is a radiopharmaceutical that binds to beta-amyloid plaques in the brain, enabling visualization via PET imaging.
For thyroid ablation or therapy of thyrotoxicosis: 100-200 mCi (3.7-7.4 GBq) orally as a single dose. For diagnostic imaging: 5-10 μCi (0.185-0.37 MBq) orally.
For diagnostic imaging: 370 MBq (10 mCi) administered as a slow intravenous bolus (approximately 1 mL/sec).
None Documented
None Documented
Physical half-life: 8.02 days. Effective half-life in euthyroid patients: ~5-7 days, but reduced to ~3-5 days in hyperthyroidism due to increased turnover. In thyroid cancer with remnant ablation, effective half-life may be longer (up to 8 days) due to reduced clearance.
Terminal elimination half-life is approximately 45-50 minutes in patients with normal renal function, allowing for rapid clearance and early imaging within 4 hours post-injection.
Primarily renal; approximately 90% excreted in urine within 72 hours, with the remainder eliminated via feces (biliary-fecal route, <10% in bile).
Primarily renal excretion as unchanged drug (90-95%) with the remainder excreted via feces (5-10%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical